Investor Alert From Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of Bradley Pharmaceuticals, Inc. - BDY
30 Maggio 2007 - 10:10PM
PR Newswire (US)
LITTLE ROCK, Ark., May 30 /PRNewswire/ -- Cauley Bowman Carney
& Williams, PLLC announces an investigation into the proposed
acquisition of Bradley Pharmaceuticals, Inc. ("Bradley"). On May
29, 2007, Bradley announced that it had received a buyout offer
from an investment group led by Chief Executive Daniel Glassman.
Under the terms of the proposal, Bradley shareholders would receive
$21.50 per share in cash for each share owned. This price per share
represents a 17% premium over the stock's closing price prior to
announcement of the merger. The company's current stock price is
over 4% above the proposed offer. If the proposed merger is
completed, Bradley will no longer be a publicly traded company.
Cauley Bowman Carney & Williams, PLLC Cauley Bowman is a
national law firm that represents investors in securities fraud and
corporate governance class actions. It is one of the country's
premier firms in the area of securities fraud having recovered
billions of dollars for defrauded investors and secured significant
corporate governance reforms. Cauley Bowman maintains in-house
finance, forensic accounting specialists and extensive trial
experience. If you are a current shareholder of Bradley
Pharmaceuticals, Inc. and would like to be advised of your rights
in this matter, you may contact Cauley Bowman Carney &
Williams, PLLC at the phone number below. CONTACT Darrin L.
Williams, Esq. Randall K. Pulliam, Esq. 1-888-551-9944 DATASOURCE:
Cauley Bowman Carney & Williams, PLLC CONTACT: Kristi Gray of
Cauley Bowman Carney & Williams, PLLC, +1-501-312-8500 Web
site: http://www.cauleybowman.com/
Copyright